Stability of 3-bromotyrosine in serum and serum 3-bromotyrosine concentrations in dogs with gastrointestinal diseases.
Academic Article
Overview
Research
Identity
Additional Document Info
Other
View All
Overview
abstract
BACKGROUND: 3-Bromotyrosine (3-BrY) is a stable product of eosinophil peroxidase and may serve as a marker of eosinophil activation. A gas chromatography/mass spectrometry method to measure 3-BrY concentrations in serum from dogs has recently been established and analytically validated. The aims of this study were to determine the stability of 3-BrY in serum, to determine the association between peripheral eosinophil counts and the presence of an eosinophilic infiltrate in the gastrointestinal tract, and to compare serum 3-BrY concentrations in healthy dogs (n=52) and dogs with eosinophilic gastroenteritis (EGE; n=27), lymphocytic-plasmacytic enteritis (LPE; n=25), exocrine pancreatic insufficiency (EPI; n=26), or pancreatitis (n=27). RESULTS: Serum 3-BrY concentrations were stable for up to 8, 30, and 180days at 4C, -20C, and -80C, respectively. There was no significant association between peripheral eosinophil count and the presence of eosinophils in the GI tissues (P=0.1733). Serum 3-BrY concentrations were significantly higher in dogs with EGE (median [range]=5.04 [0.63-26.26] mol/L), LPE (median [range]=3.60 [0.63-15.67] mol/L), and pancreatitis (median [range]=1.49 [0.63-4.46] mol/L) than in healthy control dogs (median [range]=0.63 [0.63-1.79] mol/L; P<0.0001), whereas concentrations in dogs with EPI (median [range]=0.73 [0.63-4.59] mol/L) were not different compared to healthy control dogs. CONCLUSIONS: The present study revealed that 3-BrY concentrations were stable in serum when refrigerated and frozen. No relationship between peripheral eosinophil count and the presence of eosinophils infiltration in the GI tissues was found in this study. In addition, serum 3-BrY concentrations were increased in dogs with EGE, but also in dogs with LPE and pancreatitis. Further studies are needed to determine whether measurement of 3-BrY concentrations in serum may be useful to assess patients with suspected or confirmed EGE or LPE.
